Dr. Alfred A. Bove, M.D. Joins Health Station Networks, Inc. as Chief Medical Officer

New York, NY (PRWEB) May 19, 2011

Alfred A. Bove, M.D., Ph.D., M.A.C.C., has joined Health Station Networks, Inc., (HSNI) as the chief medical officer, it was announced today by Kenneth S. Williams, chairman and CEO of the company. At the outset, Dr. Bove will author a 'white paper' which will act as a guide to the medical and social role that the Company will play over the next three years of its operations, to include the Company's strategic objectives. It will also identify how the largest network of Health Stations will fit into the new Era of Healthcare Reform.

HSNI is owned by a consortium of strategic partners from the health and wellness industry and the digital media industry, and is led by Williams. HSNI has entered into a binding letter of intent to acquire substantially all of the assets of Sentry Health which owns and operates a network of over 20,000 commercial, automated, blood pressure monitors and health stations located in pharmacies, grocery stores, worksites, medical clinics and health clubs in the United States and Canada. These health stations account for 500 million blood pressure and other non-invasive biometric measurements annually. The use of the monitors is free of charge to consumers, with advertising supporting most of this access. HSNI expects to close the acquisition of the Sentry Health assets by no later than the end of May, 2011.

Dr. Bove is the past president of the American College of Cardiology. He received his bachelor's degree in Electrical Engineering from Drexel University, and received his M.D. and Ph.D. (Physiology) degrees from Temple University Medical School in Philadelphia. In 1981, he joined the staff of the Mayo Clinic in the Division of Cardiology, and returned to Temple Hospital as the section chief in Cardiology in 1986. His research includes coronary endothelial function, myocardial function in valvular heart disease and heart failure, exercise physiology, diving and hyperbaric medicine, and medical informatics. Dr. Bove has published over 260 original research papers, and is the author of texts on Coronary Disease, Exercise Medicine, and Diving Medicine. He has received numerous awards for his work in cardiovascular medicine and environmental medicine. His military training was devoted to diving and submarine medicine including active duty at the Naval Medical Research Institute. He served two years in the U.S. Navy as an Undersea Medical Officer and served another 31 years in the Navy Reserves, retiring with the rank of Captain. He was a member of a mobile hospital staff in Operation Desert Storm in 1991.

Dr. Bove practices Clinical Cardiology with particular expertise in heart failure and heart transplantation, Undersea Medicine and Sports Medicine. He is board certified in Internal Medicine, Cardiovascular Diseases and Undersea and Hyperbaric Medicine.

In making the announcement, Ken Williams said, Dr. Bove provides HSNI with a unique understanding of the challenges and opportunities facing Healthcare in the U.S. We are about to acquire the largest network of installed blood pressure machines in the world that has started the transition into a richly featured, Internet connected, digital health station network, offering a range of critical biometric tests and tracking capabilities for individual users. His current research involves Internet-based medical information systems for management of chronic heart disease in underserved urban and rural communities. This work has brought improved quality of care in heart failure and hypertension to patients living in underserved communities and we plan to expand upon that on even a broader base for all people at risk.

Dr. Bove added, Our goal for HSNI is to accelerate this transition to the new health monitor platform and to provide more effective health risk assessment and empowerment for individuals and organizations. The sponsorship of the health stations allows prominent companies engaged in the healthcare industry to impart information about meaningful health products and services to a vast user base. This captive audience also provides the enormous and dynamic opportunity for mobile applications and the portability of personal health records that will be subscriber supported. We intend to closely align with our retailer and corporate partners to provide a consumer environment in which individuals can begin to take more control of their own personal health and wellness, and companies can help their employees by providing intervention and coaching solutions utilizing meaningful, real time data and information.

###

Ascent Scientific Licenses Novel Dynamin Toolkits from Childrens Medical Research Institute and University of Newcastle

Bristol, UK, Sydney and Newcastle, Australia (PRWEB) March 16, 2011

Ascent Scientific together with Childrens Medical Research Institute and The University of Newcastle today announced that they have entered into a license, supply and distribution agreement for a range of small molecule dynamin inhibitors for research these are novel tools for investigating cellular processes. The agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.

Dynamin is a key protein involved in the cellular process of endocytosis, a process that involves the uptake and recycling of extracellular material by mammalian cells. Endocytic pathways are also utilised by viruses and toxins to gain entry into cells. Dynamin also participates in cell cycle progression and has shown to have critical roles in centrosome cohesion and cytokinesis.

Dynamin inhibitors have applications for researchers investigating cell signalling pathways, the cell cycle and cellular division and a range of medical conditions including cancer, infectious diseases including HIV and botulism and neurological conditions such as epilepsy.

The laboratories of Professor Adam McCluskey (University of Newcastle) and Professor Phillip Robinson (Childrens Medical Research Institute) have developed the first set of rationally designed mechanism-based pharmacological inhibitors of dynamin. These inhibitors are a range of small molecule chemicals that stop endocytosis through inhibition of the GTPase dynamin, a key protein involved in the initiation and completion of endocytosis.

McCluskey and Robinson have developed a unique portfolio of multiple classes of these small molecule dynamin inhibitors. These molecular classes selectively target different domains of dynamin providing novel research tools for understanding endocytosis biology and its role in intracellular processes and disease.

Professor McCluskey said We are very pleased that these dynamin inhibitors, which we designed and developed with the intent that they be utilized to further explore the chemical biology of dynamin and endocytosis biology, will now be available to researchers worldwide through Ascent Scientific.

Professor Robinson remarked, This palette of inhibitors provides a new means to regulate dynamins activity by independent molecules and with more than one mechanism of action, allowing scientists to more definitively assign a particular biological function to dynamin. This strategy is more powerful than relying on the use of a sole inhibitor.

Steve Roome PhD, Commercial Director for Ascent Scientific, comments "These groundbreaking tools provide a means for scientists to inhibit dynamin activity, and modulate endocytosis. Potent cell-permeable in vitro and in cell based inhibitors, together with control molecules are available individually, and in kit form providing researchers with a variety of novel ways to explore dynamin-mediated cellular processes".

The dynamin inhibitors (and their respective inactive control compounds) available from Ascent Scientific include:

Iminodyn-22

Potent, broad spectrum dynamin inhibitor. IC50 values are 450 nM and 390 nM for inhibition of dynamin I and II GTPase respectively). Binds to the GTPase domain at an allosteric site and displays uncompetitive antagonism with respect to GTP. Inhibits receptor mediated endocytosis (RME) and synaptic vesicle endocytosis (SVE) ( IC50 values are 10.7 and 108